| Abstract |
[Abstract] Objective To explore amisulpride effect on serum prolactin in newly diagnosed patients with schizophrenia. Methods Selected the June 2014 - June 2015 newly diagnosed schizophrenic patients in our hospital, 87 patients received amisulpride, before comparing different gender, age, symptoms and treatment, after treatment for 4 weeks, 6 weeks, 8 weeks serum prolactin levels. Results Before treatment, no significant difference (p> 0.05) in patients diagnosed with schizophrenia different sex prolactin levels. After 4 weeks, 6 weeks, 8 weeks, patients were serum prolactin levels continue to rise, and the greater the magnitude of changes in female patients, the difference was statistically significant (p <0.05). Before treatment, no significant difference (p> 0.05) in patients with newly diagnosed schizophrenia in different age prolactin levels. After 4 weeks, 6 weeks, 8 weeks, patients were persistently elevated serum prolactin levels between the two groups was not statistically significant (p> 0.05). Before treatment, no significant difference (p> 0.05) in patients diagnosed with schizophrenia different symptoms of prolactin levels. After 4 weeks, 6 weeks, 8 weeks, patients were persistently elevated serum prolactin levels, the difference was statistically significant (p <0.05) between groups. Conclusions Amisulpride can cause newly diagnosed schizophrenic patients serum prolactin levels continue to rise, and for women and negative symptoms in patients with greater impact.
|